Gene-Edited iPSC Line Development

This contract involves the application of CRISPR-Cas12a gene editing technology to induce specific mutations in induced pluripotent stem cell (iPSC) lines that are linked to neurodegenerative diseases, including Alzheimer’s and Parkinson’s. The objective is to develop gene-edited iPSC lines that can be used for further research into these conditions. The work is to be performed in Bar Harbor, and the contract falls under the subcontract category with a NAICS code of 325412, which relates to pharmaceutical preparation manufacturing. The contract is facilitated by the National Institutes of Health under the Department of Health and Human Services, with a posting date of June 11, 2026. Interested parties must submit their responses by June 23, 2026, at 3:00 PM. Although there is no specified set-aside designation or organizational type for bidders, the nature of this highly specialized contract suggests a focus on advanced biomedical research institutions or companies with expertise in gene-editing technologies and stem cell biology.